Denise Pollard-Knight is Director at OncoMed Pharmaceuticals Inc (OMED). They have made 9 open-market trades across 1 company since 2013, most recently 2016-11-03.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.0M since 2013, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OMED | SELL | 2014-12-31 | 2015-01-02 | $21.66 | $82K | -32.1% | -0.5% | -0.5% |
| OMED | SELL | 2014-12-26 | 2014-12-30 | $21.63 | $381K | -32.1% | -0.5% | -0.5% |
| OMED | SELL | 2014-12-19 | 2014-12-23 | $21.71 | $448K | -32.1% | -0.5% | -0.5% |
| OMED | SELL | 2014-12-08 | 2014-12-10 | $21.77 | $717K | -32.1% | -0.5% | -0.5% |
| OMED | SELL | 2014-12-05 | 2014-12-05 | $21.60 | $540K | -32.1% | -0.5% | -0.5% |
| OMED | SELL | 2014-06-30 | 2014-07-02 | $23.59 | $271K | -32.1% | -0.5% | -0.5% |
| OMED | SELL | 2014-06-25 | 2014-06-27 | $23.56 | $77K | -32.1% | -0.5% | -0.5% |
| OMED | SELL | 2014-06-23 | 2014-06-25 | $24.09 | $1.6M | -32.1% | -0.5% | -0.5% |
| OMED | BUY | 2013-07-23 | 2013-07-23 | $17.00 | $1.0M | -32.1% | -0.5% | -0.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.